Last updated: February 24, 2026
What is NDC 72578-0120?
NDC 72578-0120 corresponds to Aflibercept Injection, branded as EYLEA. It is used primarily for treating neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular diseases.
Market Overview
Market Size and Revenue (2022-2023)
EYLEA generated approximately $4.7 billion globally in 2022, according to IQVIA data. The U.S. accounts for roughly 65% of this revenue, equating to approximately $3 billion.
Key Competitors
- Ranibizumab (Lucentis)
- Bevacizumab (Off-label use for similar indications)
- Faricimab (Vabysmo), FDA approved in January 2022
Market Trends
- Growing prevalence of AMD and diabetic eye diseases in aging populations.
- Increased adoption of anti-VEGF therapies, with EYLEA maintaining leading market share.
- Emergence of biosimilar and novel agents, affecting pricing and market dynamics.
Geographic Market Breakdown
| Region |
Market Share |
Revenue (2022) |
Growth Rate (Compound Annual, 2018-2022) |
| North America |
60% |
$2.8 billion |
7.5% |
| Europe |
20% |
$940 million |
6.2% |
| Asia-Pacific |
15% |
$705 million |
10.8% |
| Rest of World |
5% |
$235 million |
4.8% |
Pricing Analysis
Current List Price
- U.S. (per 2-mL vial): $1,850–$2,000
- Average wholesale acquisition cost (WAC): ~$1,950
- Per dose basis: Approximate cost of $1,850–$2,000 per injection, with treatment regimens typically requiring monthly injections initially, then bimonthly or quarterly.
Reimbursement Landscape
Medicare Part B reimbursement rates approximate $1,900 per injection, with some variations based on billing codes and discounts.
Volume and Utilization
- Patients typically require 7-8 injections in the first year, decreasing in subsequent years.
- Annual treatment volume in the U.S. exceeds 1.2 million injections, representing a significant revenue base.
Price Trends
- Moderate increases in list prices over the past five years (~2-3% annually).
- Introduction of biosimilars and competitors could exert downward pressure on pricing in the long term.
Price Projection (Next 3-5 Years)
| Year |
Expected Price Range (per injection) |
Rationale |
| 2024 |
$1,850–$2,050 |
Stable market with slight inflation, potential initial biosimilar competition in select regions. |
| 2025 |
$1,850–$2,100 |
Possible price stabilization; early biosimilar entry in Europe and Asia. |
| 2026 |
$1,850–$2,150 |
Biosimilars may impact pricing, especially outside North America. |
| 2027 |
$1,850–$2,200 |
Continued competition could lead to slight reductions in some markets; premium pricing maintained in the U.S. due to brand loyalty. |
| 2028 |
$1,850–$2,250 |
Market saturation and biosimilar penetration elsewhere likely to influence pricing downward, but U.S. prices stable. |
Potential Market and Price Drivers
- Biosimilar Entry: Expected within 3-5 years in Europe, possibly earlier in other markets.
- Regulatory Approvals: New indications or formulations could expand market share.
- Patent Status: U.S. patent expiry for EYLEA is expected around 2024-2025, opening up generic competition.
- Cost-Containment Policies: Payer push to reduce drug costs, especially for off-label use with cheaper alternatives like off-label Bevacizumab.
Conclusion
EYLEA (NDC 72578-0120) maintains a dominant market position due to efficacy and brand recognition, with stable pricing expected in the near term. Long-term, biosimilar competition and patent expiries could pressure prices downward, especially outside North America.
Key Takeaways
- The global market for aflibercept is approximately $4.7 billion, with U.S. sales representing about two-thirds.
- Current list prices hover around $1,850–$2,000 per injection, with steady annual increases.
- Price projections suggest stability through 2024, with slight increases thereafter due to market dynamics.
- Biosimilar competition expected to emerge in 3-5 years, likely influencing future pricing strategies.
- Cost containment efforts by payers could accelerate price reductions outside the U.S.
FAQs
1. What factors influence the pricing of EYLEA?
Pricing is shaped by patent exclusivity, market competition (biosimilars), reimbursement policies, and demand for treatment.
2. How might biosimilar competition impact EYLEA prices?
Biosimilars typically launch at 20-30% lower than the reference product, exerting downward pressure on prices over time.
3. Are there any upcoming patent expirations for EYLEA?
Patent protection is expected to expire around 2024-2025, opening opportunities for generic or biosimilar entrants.
4. How do regional differences affect EYLEA pricing?
Prices are higher in the U.S. due to less aggressive price controls. Europe and Asia see generally lower prices due to government negotiations and market conditions.
5. What is the future outlook for EYLEA’s market share?
While it remains the market leader for retinal diseases, new entrants and biosimilars may erode its market share gradually, especially outside North America.
Sources
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. (2022). Vabysmo (Faricimab) Approval.
[3] GoodRx. (2023). EYLEA Price and Cost.
[4] RAPS. (2022). Patent Status and Biosimilar Launches.
